All News
Filter News
Found 808,674 articles
-
IHI Convenes 32nd Annual Forum on Quality Improvement in Health Care
12/8/2020
Leaders and clinical improvers gather virtually to share new ideas and evidence-based approaches to improve population health and health equity
-
American Cancer Society Announces New Members and Officers of Board of Directors
12/8/2020
The American Cancer Society has named four new members and elected five new officers to its board of directors, with all terms beginning on January 1, 2021.
-
HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
12/8/2020
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq technology.
-
Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay
12/8/2020
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene ® platform. The SARS-CoV-2 test is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus, the
-
Saphena Medical’s Venapax® EVH System Awarded Sole-Supplier Contract With Premier Inc.’s ASCEND Purchasing Program
12/8/2020
Saphena Medical, makers of Venapax, unitary endoscopic vessel harvesting system, announced today that it has been awarded a contract with Premier’s highly committed ASCEND (Accelerated Supply Chain Endeavor) program in the category of Endoscopic Vessel Harvesting. Premier Inc. is one of the largest performance improvement companies in the U.S.
-
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease
12/8/2020
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces preliminary data from its open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector (AAV)-based gene therapy candidate expressing LAMP2B for the treatment of Danon Disease
-
Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officer
12/8/2020
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment of Gary Fortin as Chief Operating Officer (COO). Prior to joining ShapeTX, Dr. Fortin was Head of Business Strategy and Operations for the Severe Genetic Disease unit of bluebird bio (NASDAQ:BLUE), where he navigated a portfolio of gene therapy programs through
-
CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction
12/8/2020
CV Sciences, Inc., a preeminent supplier and manufacturer of hemp cannabidiol products, announced that it has entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC.
-
Delcath Systems Announces Proposed Public Offering of Common Stock
12/8/2020
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering
-
Neurotrope, Inc. Completes Independent Spin-off of Neurotrope Bioscience, Inc. and is Renamed Synaptogenix, Inc.
12/8/2020
Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., today announced the successful spin-off of substantially all of the legacy assets and liabilities of Neurotrope, Inc. into the newly renamed company which is trading under the new symbol: SNPX.
-
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred Stock
12/8/2020
HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it intends to offer and sell shares of its common stock and shares of Series A convertible preferred stock in an underwritten public offering (the “Offering”)
-
Neumentum to Present New Data for Drug Candidate NTM-001 at the 2020 ASHP Midyear Clinical Meeting and Exhibition
12/8/2020
Neumentum Inc ., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present three posters at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, being held virtually December 6-10, 2020. The following poster presentations will be available on-demand at the ASHP Midyear Meeting and Exhibition website on Tuesday, December 8, 2020, 3:00 – 4:30 pm
-
Amolyt Pharma Announces Research Collaboration with PeptiDream Amolyt and PeptiDream
12/8/2020
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration whereby both companies will work together to test and optimize growth hormone receptor antagonist (GHRA) peptides, with the goal of selecting a candidate for clinical development as a potential tre
-
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
12/8/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT-801. ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), which is expected to affect more than 13 million adults in the United States. The Ph
-
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem
12/8/2020
Hyundai Bioscience (KOSDAQ symbol: 048410) released a report on December 8 th that CP-COV03 , its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activity with a single administration. This pharmacokinetics study was recently p
-
iX Biopharma's Xativa(TM) bags "CBD Product of the Year" accolade from the Australian Cannabis Industry Awards 2020
12/8/2020
Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) ("iX Biopharma", "the Company", or together with its subsidiaries, "the Group") is pleased to announce that Xativa™, the Group's novel sublingual medicinal cannabidiol ("CBD") wafer, clinched the "CBD Product of the Year" accolade presented by the Cannabis Industry Awards 2020
-
Chiesi USA Appoints Jon Zwinski as General Manager and Chief Executive Officer
12/8/2020
Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has announced the appointment of Jon Zwinski as General Manager and Chief Executive Officer of Chiesi USA to advance the company’s global therapeutic efforts. Effective Jan. 1, 2021, Mr. Zwinski will succeed President and CEO K
-
BIOREM Announces Successful Demonstration Projects Assessing Novel Biological Processes for the Mitigation of Industrial VOC Emissions
12/8/2020
BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced the successful completion of two research projects for the mitigation of volatile organic compounds from complex industrial gas emissions. Both projects were to assess and compare the efficacy of BIOREM's enhanced biological processes against legacy
-
JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection
12/8/2020
-T1Detect makes T1D screening easier and more accessible with unrestricted eligibility requirements for at-home testing and financial assistance-
-
Boost Biomes announces extension of Series A with new investor, Universal Materials Incubator
12/8/2020
US-based food and agriculture biotech startup Boost Biomes and Japanese investment company Universal Materials Incubator (UMI) announced today the close of $2M extended series A equity round. The firs